




***42nd Annual J.P. Morgan
Healthcare Conference***
January 8, 2024

Jerrell Shelton



Forward Looking Statements

Statements in this presentation which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, plans, strategy, acquisitions, future financial results and financial condition, projected trends in the market in which the Company operates, and regulatory approvals with respect to the products of the Company's clients. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors discussed in the Company's Securities and Exchange Commission ("SEC") reports including, but not limited to, the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and any subsequent filings with the SEC. The forward-looking statements contained in this presentation speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this presentation.

Agenda

1. Introduction to Cryoport
2. 2023 in Review
3. Projects Underway
4. Outlook for 2024 and Beyond



Introduction to Cryoport

Cryoport provides . . .

. . . groundbreaking, efficient, rapidly scalable, supply-chain innovation across the life sciences supply chain by:

- Ensuring effective product management through highly differentiated temperature-controlled logistics, shipping systems, and condition monitoring
- Protecting critical therapies, treatments, and research utilizing our extensive biostorage, kitting, fulfillment, and QP services
- Supplying cryogenic storage and transportation systems
- Providing professional consulting
- And soon, providing optimized, scalable apheresis cryo-preservation and distribution

We have earned the reputation of being the life sciences industry's most trusted partner by providing market driven solutions to our clients, which gives them safe, dependable, and timely access to their respective markets and clients.




We are a Trusted Partner to Life Sciences Companies

- **We provide mission critical services** with ever-evolving core competencies to cryopreserve, precision store, package, ship, deliver, kit, label, and fulfill biopharma products with precision temperature-controlled solutions for:
 - Cell and gene therapies
 - Upstream & downstream commodities
 - Cellular therapy starting materials
 - Human and animal reproductive materials
- **Recognized leader** in the biopharma and cell & gene therapy supply chain
- **Leading global manufacturer** of cryogenic systems for the life sciences
- **One of the largest global biopharma** specialty couriers




Unique Platform Supporting the Cell Therapy Workflow



Cryoport's Evolution

72% Revenue CAGR Since 2012



Notes: (1) Guidance (mid-point)

Global Network Supporting the Life Sciences




17 countries
50 facilities



Cryoport Systems' Clinical Trial Support

Q3 2023 - 81 Phase III Clinical Trials Supported by Cryoport





2023 in Review

2023 in Review

- **Business Development**
- **Site Developments**
- **Infrastructure Developments**
- **Acquisitions**

2023 In Review

14 Commercial Therapies Currently Supported

Company	Therapy	Indication	~Patient Population/Year
Orchard Therapeutics	Libmeldy	Metachromatic Leukodystrophy	25
Orchard Therapeutics	Strimvelis	Adenosine Deaminase Deficiency	19
Bristol Myers	Breyanzi	Large B-cell Lymphoma	78,000
Bristol Myers	Abecma	Multiple Myeloma	80,000
Crispr and Vertex	Casgevy	Sickle Cell Disease	25,000
Novartis	Kymriah	Large B-cell Lymphoma	78,000
J&J/Legend	Carvykti	Multiple Myeloma	80,000
Gilead	Yescarta	Large B-cell Lymphoma	78,000
Gilead	Tecartus	Mantle Cell Lymphoma	13,000
bluebird bio	Lyfgenia	Sickle Cell Disease	25,000
bluebird bio	Zynteglo	Transfusion-Dependent Thalassemia	600
bluebird bio	Skysona	Cerebral Adrenoleukodystrophy	34
Sarepta	Elevidys	Duchenne Muscular Dystrophy	3,300
Atara	Ebvallo	Epstein-Barr Virus	4,000

2023 in Review

Business Development

○ Key new clients

- Sanofi S.A.
- Laboratoires Pierre Fabre
- Rocket Pharmaceuticals
- Cabaletta Bio, Inc.
- Vertex Pharmaceuticals/CRISPR Therapeutics
- ProKidney
- Arcellx
- Inception Fertility, LLC

○ Product/service launches

- Elite™ UltraCold -80°C shipper
- Bioservices' kitting services in Morris Plains, NJ
- Cryoport Systems' Logistics Centers
 - ✓ Catapult Cryo-hub in Stevenage, UK
 - ✓ Tokyo, Japan
- CryoShuttle services in Washington, DC
- Fusion 2 8000 freezer model

2023 in Review

Site Developments

CRYOGENE

- Houston, TX - completed expansion of biostorage to 84,000 sq. ft.

CRYOPDP

- Tokyo, JP - Logistics Center co-located with Cryoport Systems
- Brisbane, AU - Logistics Center opened
- Lyon, FR - Logistics Center opened
- Belgium, Netherlands, USA, France & Poland - Good Distribution Practices (GDP) certifications

Cryoport Systems

- Sydney, AU - Logistics Center with co-location synergy with CRYOPDP

2023 in Review

Infrastructure Releases

- **Cryoportal® 2 Logistics Management Platform**
 - GAMP 5 validated for pharmaceutical industry
 - Comprehensive ERP system that includes order management, fleet management, requalification, and client support
 - Allows API connections to partners and clients

- **Further implementation of UnITy ERP**
 - Includes Transport Management System and further digitizes CRYOPDP processes from order to cash
 - Implemented in France, USA, Singapore, South Korea, Poland, Ireland, Spain, Japan, Netherlands, Belgium
 - To be implemented in India and UK
 - API to connect to Cryoportal® 2.0 Logistics Management Platform

2023 in Review

Acquisitions

- **BlueBird Express**

- Support to speed up CRYOPDP's US expansion

- **Tec4med™**

- Integrating technology across all business units
- Advance software/data platform that is fully customizable



Projects Underway

Projects Underway

- Hardware/Communications Software
- Products
- Facilities
- Other

Projects Underway

Hardware/Communications Software

○ Skytrax™ Condition Monitoring System

- Providing multiple redundancies for the most reliable condition monitoring in the life sciences
- Equipped with advanced sensors

○ Tec4med™

- Advanced software/data platform that is fully customizable
- Integrating technology across all business units that will eventually connect condition monitoring technologies for dewars, freezers and Cryoport Express® and Cryoport Elite™ Shippers and provide the cell & gene therapy with its most comprehensive Chain of Compliance®

Projects Underway

Products

Cryoport Systems

- **HV-3 shipper** - client driven requests to reduce shipping costs and accommodate mobility and capacity needs, clearly differentiated
- **Cryosphere** - revolutionary, unique cryoshipper with maximum certainty of performance regardless of environment

MVE Biological Solutions

- **Fusion 2.0 line** - requires no plumbing
- **Next generation cryogenic freezer** - with advanced controller, electronics, and ergonomics

Projects Underway

Facilities

Cryoport Systems

- Houston, TX & Liege, BE, IntegriCell, operational 2024
- Paris, FR, Global Supply Chain Center, operational 2024
- Santa Ana, CA - Global Supply Chain Center, operational 2025
- Stevenage, UK - Global Supply Chain Center, operational 2026

CRYOGENE

- USA, Project Blue, a 35,000 square foot state of the art biostorage operation, operational 2025
- San Antonio, TX, biostorage operation to be ramp up beginning first quarter, 2024
- Houston, TX, joint venture with Texas Children's Hospital and Baylor College of Medicine for automated sample storage to ramp up beginning first quarter, 2025

CRYOPDP

- Chicago, IL and Houston, TX, Logistics Centers for specialty courier operations

MVE Biological Solutions

- New Prague, MN, completing manufacturing facility expansion
- Chengdu, CN, expansion of plant to produce cryogenic freezers in market

Projects Underway

Other

- **Drive to profitability** - EBITDA optimization projects across the company
- **Corporate rebrand** - underway



Outlook for 2024 and Beyond

Outlook for 2024 and Beyond

We plan to continue to **grow organically and through acquisitions**. We also plan to continue to build out our platform to better **serve Life Sciences through partnerships and collaborations** with leading companies.

We will provide our 2024 financial outlook when reporting our 2023 year end results.

We believe **cell & gene therapy is poised for significant growth** over the years to come as these therapies become commercial and are more widely adopted for the treatment of an increasing range of medical conditions.

We believe the world is in the beginning of a transformation in the way medicine is practiced because as technology improves, cell and gene therapies will become even more effective and widely adopted, transforming the way we approach and treat chronic medical conditions.


Outlook for 2024 and Beyond

Saving life; Sustaining life; Creating life

From Emily Whitehead to Danny Brooks and all those in between, we are making progress.

The future of regenerative medicine continues to advance and Cryoport is assisting as we improve the quality of life for humanity around the world.

Emily Whitehead – 11 years cancer free.





Cryoport

Enabling the Future of Medicine

Thank you!